GlassScriptPhysician profile
David L Struble
NPI 1710919352
$3,726.84
in general payments reported to CMS, 2019-2025
18 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $663 · 2021: $482 · 2022: $617 · 2023: $877 · 2024: $512 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $668.22 | 2021-2025 | Caplyta |
| Abbvie INC. | $637.98 | 2021-2024 | Vraylar |
| Sunovion Pharmaceuticals INC. | $566.44 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $519.68 | 2020-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $243.69 | 2020-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $200.94 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $195.23 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $182.99 | 2021-2023 | Trintellix |
| Alkermes, INC. | $137.95 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $110.62 | 2020-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $85.15 | 2022-2024 | |
| Axsome Therapeutics, INC. | $59.02 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $47.77 | 2020-2025 | Fanapt |
| Merck Sharp & Dohme LLC | $16.00 | 2023 | Belsomra |
| Tris Pharma INC | $15.16 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $14.65 | 2022 | |
| Alfasigma USA, INC. | $13.17 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Struble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.